| 10/7/2008 | CVDD | AtheroGenics agrees to convert case to Chapter 11, plans to sell assets
|
| 9/16/2008 | CVDDSS | AtheroGenics noteholders file involuntary Chapter 7 bankruptcy petition
|
| 9/2/2008 | CVDDSS | AtheroGenics to skip note payments, evaluate restructuring alternatives; noteholder proposal rejected
|
| 8/20/2008 | CVDDSS | AtheroGenics considering exchange of 4.5% convertible notes
|
| 8/11/2008 | CVDDSS | AtheroGenics considers bankruptcy as one convertible repayment option
|
| 5/9/2008 | CVDDSS | AtheroGenics 4.5% convertibles repayment to leave company short of cash for 2009
|
| 1/9/2008 | CV | AtheroGenics extends maturity profile by restructuring $17.5 million of 4.5% convertibles
|
| 11/26/2007 | CV | Market Commentary: Countrywide, Fannie Mae, E*Trade down as financials tumble; SunPower, Suntech Power brighten dark day
|
| 11/12/2007 | CV | Market Commentary: E*Trade shellacked; AtheroGenics whacked; Suntech, SunPower smacked; AMR, Continental soar
|
| 6/25/2007 | CV | AtheroGenics exchanges for 4.5% convertibles
|
| 6/22/2007 | CV | AtheroGenics plans exchange for 4.5% convertibles
|
| 3/28/2007 | CV | Market Commentary: Beazer firm on probe; AtheroGenics falls on reports; Equinix gains, Kilroy flat on debuts; five deals launch
|
| 3/27/2007 | CV | Market Commentary: CV Therapeutics, AtheroGenics gain on data; Equinix higher, Kilroy quiet in gray
|
| 3/19/2007 | CV | Market Commentary: AtheroGenics falls; Host Hotels, Freeport-McMoran up in gray; ProLogis, ViroPharma, Pioneer plan deals
|
| 1/11/2006 | BTCV | AtheroGenics exchanges $14 million 4.5% convertibles for stock
|
| 12/22/2005 | CV | Market Commentary: Cephalon convertibles gain on patent agreement; SFBC up on possible sale; Albertson's, Placer lose
|
| 12/13/2005 | BTCV | New Issue: Lehman prices $12.5 million Yeelds linked to AtheroGenics
|
| 8/26/2005 | CV | Market Commentary: DOV Pharmaceutical convertibles tumble; Atherogenics adds; Agilent active on call news
|
| 1/12/2005 | CV | AtheroGenics greenshoe exercised, raising convertibles to $200 million
|
| 1/7/2005 | CV | Market Commentary: AtheroGenics ends at 100.5; Western Wireless steady; Cap Gemini pressures techs
|
| 1/7/2005 | CV | New Issue: AtheroGenics sells upsized $175 million convertible to yield 1.5%, up 35%
|
| 1/6/2005 | CV | Market Commentary: Western Wireless comes in on Alltel deal buzz; Citizens gains; Leucadia off; AtheroGenics up
|
| 1/5/2005 | CV | AtheroGenics $125 million convertible talked to yield 1.5%-2.0%, up 30%-35%
|
| 1/5/2005 | CV | Market Commentary: Celanese, AtheroGenics talk emerges; Delta cuts fares but convertibles quiet; OMI firmer
|
| 10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
| 9/28/2004 | CV | Market Commentary: Human Genome up 1.5 in gray on tighter talk; Calpine, American Financial issues up; Lions Gate emerges
|
| 9/27/2004 | CV | Market Commentary: Human Genome, American Financial deals emerge; new Calpine issue quiet; AtheroGenics soars after-hours
|
| 12/8/2003 | CV | Market Commentary: Issuers unwrap $1.73 billion of new paper and more set to come this week, this month
|
| 8/19/2003 | CV | AtheroGenics greenshoe exercised, raising convertibles to $100 million
|
| 8/14/2003 | CV | New Issue: AtheroGenics sells upsized $80 million convertible at 4.5%, up 22.5%
|
| 8/13/2003 | CV | Market Commentary: New deal train chugs slowly along with string of small deals; dividend risk still high profile
|
| 8/12/2003 | CV | AtheroGenics plans $75 million convertible offering
|
